Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: AMGN.NASDAQ
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Amgen (AMGN) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

NEUTRAL

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

NEUTRAL

$399

+3.5%+5.8% incl. dividends

2031

5-Year

NEUTRAL

$512

+32.8%+48.0% incl. dividends

Published batch insight

Biotech Giant Balances Looming Patent Cliffs Against High Margin Pipeline Renewal

Analysis reveals high consensus that commercial expansion across core growth pillars and over ten billion dollars in free cash flow absorb severe denosumab patent erosion. However, sharp divergence persists regarding whether pipeline assets can overcome elevated balance-sheet debt and high-rate valuation compression.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Universal Investor (Polymath), Warren Buffett (Value Purist), Elon Musk (Visionary), Sherlock Holmes (Whistleblower), Ray Dalio (Strategist), Superintelligence (Anthropologist), J.P. Morgan (Titan), Michael Burry (Vulture), Machiavelli (Insider). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Amgen at the forecast anchor (2026-09-18): $14,805 in five years versus $13,892 for S&P 500 benchmark.

Amgen · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 2.2% net dividend yield for Amgen.

Figure: Five-year synthesized consensus value path for Amgen compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 385.65 USD1-year price return: +3.49%5-year price return: +32.78%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	386.58	+0.24%	+0.24%	Volume growth across cardiovascular and rare-disease portfolios absorbs initial denosumab biosimilar discounting. However, persistent five percent Treasury yields and high refinancing costs constrain broad equity multiple expansion, maintaining range-bound valuation consolidation.
Q1 2027	385.93	-0.17%	+0.07%	Statutory Medicare price resets take effect on mature blockbusters while denosumab erosion accelerates in domestic formularies. Modest top-line gains from younger specialty products keep overall corporate net earnings stable but muted.
Q2 2027	392.80	+1.78%	+1.85%	Initial Phase 3 MARITIME trial disclosures demonstrate viable monthly metabolic weight loss with manageable titration profiles. Relief over pipeline viability sparks institutional accumulation, partially offsetting ongoing European biosimilar price concessions.
Q3 2027	399.12	+1.61%	+3.49%	Consistent free cash flow generation enables scheduled debt repayments, gradually improving interest coverage. Steady volume gains across Repatha and Tezspire help insulate operating profitability against wider macroeconomic monetary tightness.
Q4 2027	408.18	+2.27%	+5.84%	Comprehensive registrational data disclosures de-risk metabolic filing timelines. A scheduled step-down in Horizon intangible amortization improves reported earnings, supporting positive sentiment and measured equity multiple stabilization into year-end.
Q1 2028	413.43	+1.29%	+7.20%	Formal regulatory submissions for MariTide progress alongside steady international rare-disease expansion. Solid operational cash conversion cushions elevated clinical development spending, keeping quarterly net income on a dependable footing.
Q2 2028	423.35	+2.40%	+9.77%	Expansion in oncology indications, notably Imdelltra, diversifies high-margin specialty revenue. Continuing debt reduction lowers net leverage toward target parameters, reinforcing credit health and improving through-cycle valuation support.
Q3 2028	429.19	+1.38%	+11.29%	Pre-launch commercial manufacturing investments for metabolic candidates elevate operating expenditures. Denosumab revenue erosion approaches a predictable baseline, allowing specialty volume compounding to become the dominant earnings driver.
Q4 2028	438.37	+2.14%	+13.67%	Regulatory approval of MariTide for chronic weight management activates initial wholesale distribution stocking. Prescribers welcome once-monthly dosing options, triggering an initial commercial re-rating despite intense incumbent competitive rebate walls.
Q1 2029	444.90	+1.49%	+15.36%	Commercial rollout commences with steady commercial payer coverage adoption. Heavy launch promotional spending and competitive pricing discounts in primary-care channels keep initial operating margin expansion measured rather than explosive.
Q2 2029	452.19	+1.64%	+17.25%	Patient adherence data confirms commercial demand for extended monthly dosing intervals. Accelerating sales across orphan therapies and internal biosimilars comfortably outpace residual mature-product decay, driving solid quarterly revenue expansion.
Q3 2029	459.90	+1.70%	+19.25%	Further amortization step-downs mechanically lift reported net income toward underlying operating cash levels. Stable macroeconomic conditions and dependable free cash conversion attract defensive value allocations to common shares.
Q4 2029	466.71	+1.48%	+21.02%	International regulatory approvals expand global distribution scale for newer metabolic and oncology assets. Annual free cash flow approaches eleven billion dollars, prompting management to evaluate renewed share repurchase capacity.
Q1 2030	473.06	+1.36%	+22.67%	First-quarter results reflect robust organic volume growth across specialized franchises, fully overcoming historical denosumab patent losses. Net leverage normalization lowers borrowing costs, bolstering per-share equity earnings growth.
Q2 2030	478.32	+1.11%	+24.03%	Class-wide pricing competition from emerging oral metabolic therapies moderates realized net unit realizations. Amgen's automated biomanufacturing scale defends operating margins, preserving steady mid-single-digit consolidated profit compounding.
Q3 2030	484.70	+1.33%	+25.68%	Long-term cardiovascular outcomes trial data broaden metabolic label indications and improve insurance reimbursement access. Sustained cash collection supports continued progressive dividend compounding and balance-sheet fortifying.
Q4 2030	493.04	+1.72%	+27.85%	Management resumes opportunistic common share repurchases as balance-sheet leverage reaches pre-acquisition benchmarks. Lower diluted share counts enhance earnings per share, driving constructive fourth-quarter performance.
Q1 2031	496.97	+0.80%	+28.87%	Terminal exclusivity shifts across legacy immunology blockbusters generate transient headline noise. However, broad diversification across rare-disease, cardiovascular, and metabolic lines insulates consolidated corporate cash flow.
Q2 2031	504.88	+1.59%	+30.92%	Next-generation bispecific oncology and autoimmune candidates advance into pivotal clinical testing. High recurring operational cash flow protects valuation multiples from late-cycle macroeconomic growth fluctuations.
Q3 2031	512.08	+1.43%	+32.78%	The five-year transformation culminates with Amgen operating as a fully de-leveraged, high-margin biopharmaceutical leader. Durable orphan drug cash flows and metabolic revenues anchor long-term intrinsic compounding.

Amgen's investment thesis centers on an operational race between structural patent attrition and specialized volume compounding. The base case establishes that six growth drivers—spearheaded by Repatha, Evenity, Tezspire, and Horizon orphan therapeutics—generate twenty-six percent volume growth, comprising seventy percent of product sales and insulating gross revenue against denosumab biosimilars and Medicare price caps. Valuation sensitivity remains acutely tied to the cost of capital. Carrying over fifty billion dollars in debt amid elevated benchmark yields caps forward price-to-earnings multiples near seventeen times forward non-GAAP earnings, as scheduled amortization runoff converges reported figures with cash realities. The primary counterargument warns that aggressive incretin rebate walls and tolerability-driven dropouts could turn pipeline assets into modest commercial contributors rather than transformative blockbusters.

Key insights

Scheduled intangible amortization runoffs mechanically compress headline price-to-earnings multiples from twenty-four times toward seventeen times without requiring operational margin expansion.
Operating cash flow exceeding ten billion dollars annually prioritizes balance-sheet deleveraging over share buybacks, systematically converting enterprise value into per-share equity value.
Counter-cyclical internal biosimilars and orphan rare-disease monopolies insulate cash conversion from broader statutory price negotiation and primary-care payer rebate pressure.

Deep Dive

The market crowd views Amgen through an oversimplified binary lens: either a declining dividend utility crippled by denosumab patent expiries and fifty billion dollars in acquisition debt, or an emergent obesity titan destined to effortlessly claim market share with MariTide. Consensus models anchor heavily on headline patent erosion while assuming speculative incretin cash flows will arrive without commercial friction.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates value by fixating on headline patent cliffs while missing the underlying compounding engine. Amgen's six core growth drivers already represent nearly seventy percent of sales, compounding at twenty-six percent and generating over ten billion dollars in annual free cash flow. This volume momentum replaces legacy revenue loss organically. Furthermore, mechanical runoff of Horizon amortization will compress trailing GAAP multiples toward forward cash realities, creating an underappreciated earnings floor.

Repricing catalyst

Pivotal Phase 3 MARITIME clinical readouts and initial post-patent denosumab guidance in 2027 represent the decisive trigger. Demonstrating competitive monthly weight maintenance alongside volume-driven top-line stability across Repatha and Uplizna will force analysts to dismantle patent-cliff collapse models, re-underwriting Amgen as a durable specialty compounder.

Published consensus context

Macro regime alignment

The prevailing macroeconomic regime of restrictive policy rates and elevated benchmark Treasury yields is a distinct headwind for Amgen's debt-heavy balance sheet. Higher refinancing rates increase debt-servicing friction on fifty-plus billion dollars of obligations and compress equity valuation multiples. However, highly inelastic healthcare demand and ten billion dollars in free cash flow provide superior defensive earnings resilience.

Published consensus context

Advisor disagreement

The central disagreement across research reports concerns whether pipeline execution and orphan-drug volume can fully overcome simultaneous patent cliffs and high leverage. Optimistic analyses model MariTide capturing a major share of the global obesity market, driving operating margins above forty percent. Conversely, skeptical assessments emphasize that denosumab biosimilar cannibalization and Medicare price negotiations will strip billions in high-margin cash flow before pipeline assets scale, while elevated refinancing rates on fifty billion dollars of debt constrain buybacks. Observing Phase 3 discontinuation rates and quarterly gross margin stabilization through 2027 will definitively resolve this debate.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Commercial growth engine outruns patent erosion: Six core commercial pillars—led by Repatha, Evenity, Tezspire, and Uplizna—generate twenty-six percent year-over-year volume growth and account for nearly seventy percent of product revenue. This broad-based momentum reliably absorbs impending denosumab biosimilar revenue losses, protecting baseline operating cash generation across the five-year forecast horizon. Expected impact: +22%.
MariTide monthly metabolic commercial launch: Pivotal Phase 3 MARITIME trials validate a differentiated once-monthly or bimonthly antibody-peptide mechanism for chronic weight management. Extended dosing intervals address major patient compliance bottlenecks in incretin therapies. Securing commercial approval unlocks high-margin revenue streams that drive durable operating earnings growth and terminal value expansion. Expected impact: +20%.
Horizon rare disease integration and cash extraction: Acquired rare-disease assets, including Tepezza, Uplizna, and Krystexxa, deliver non-discretionary revenue streams characterized by zero demand elasticity and strong gross margins. Global commercial rollout and subcutaneous delivery reformulations expand international patient cohorts, generating highly predictable operating cash flows insulated from primary-care formulary rebate wars. Expected impact: +14%.
Post acquisition deleveraging restores capital return: Annual free cash flow exceeding ten billion dollars enables systematic retirement of Horizon acquisition debt, lowering annual interest expenses by hundreds of millions of dollars. Normalizing balance-sheet leverage toward investment-grade targets improves credit metrics, paving the way for progressive dividend growth and eventual share repurchase reauthorization. Expected impact: +11%.

Top frictions and headwinds

Denosumab biosimilar patent cliff erosion: Loss of exclusivity on Prolia and Xgeva unleashes multi-competitor biosimilar launches across domestic and international markets, driving franchise revenue down thirty to forty percent. This rapid pricing and volume deflation permanently eliminates billions in high-margin operating profit, creating a mechanical drag on consolidated top-line growth. Expected impact: -17%.
Medicare statutory drug price negotiation compression: Implementation of Inflation Reduction Act Maximum Fair Price mandates enforces steep statutory price discounts on mature blockbusters like Enbrel. Mandatory government discounting compresses gross-to-net realizations and triggers spillover rebate concessions into commercial insurance formularies, permanently capping domestic pricing power on key established therapeutics. Expected impact: -13%.
Incretin market competitive crowding and discounting: Entrenched pharmaceutical duopolies and emerging oral incretin alternatives fiercely contest metabolic market share through aggressive formulary rebates and scaled manufacturing. MariTide faces substantial contracting barriers and gross-to-net discounting, capping ultimate commercial net price realization below initial peak-sales market expectations. Expected impact: -10%.
Elevated debt servicing under restrictive monetary policy: Carrying over fifty billion dollars in gross debt in an elevated interest-rate environment imposes significant carrying costs. Refinancing low-coupon legacy notes at prevailing yields elevates debt-servicing expense, absorbing operating cash flow that would otherwise fund discretionary capital returns and suppressing valuation multiples. Expected impact: -8%.

Tail risks

MariTide Phase 3 tolerability failure: Pivotal MARITIME readouts reveal severe gastrointestinal toxicities and patient discontinuation rates exceeding twenty percent despite dose titration. Eliminating Amgen's primary metabolic growth narrative destroys its valuation premium, triggering immediate multiple contraction back toward low-growth legacy pharmaceutical baselines. Probability: +28%. Expected impact: -25%.
Aggressive legislative expansion of price controls: Federal legislation expands Medicare price-setting to physician-administered Part B biologics while invalidating defensive patent thickets. Mandatory price cuts sweep across core oncology and cardiovascular portfolios, stripping billions in operating cash flow and threatening balance-sheet deleveraging schedules. Probability: +25%. Expected impact: -20%.

Tail opportunities

MariTide superior cardiovascular outcomes label: Registrational Phase 3 trials demonstrate statistically superior reduction in major adverse cardiovascular events alongside pristine monthly tolerability. Commercial and Medicare payers mandate preferred first-line coverage, propelling peak annual sales beyond ten billion dollars and prompting aggressive institutional multiple expansion. Probability: +35%. Expected impact: +28%.
Oncology bispecific BiTE solid tumor breakthrough: Accelerated registrational trial readouts expand bispecific T-cell engager therapies, spearheaded by Imdelltra, into frontline solid tumors including lung and prostate malignancies. This technological validation unlocks unforecasted high-margin oncology revenue, expanding gross margins and re-rating corporate research productivity. Probability: +28%. Expected impact: +20%.

What to monitor

Thesis watchpoints

-- Core growth drivers sustaining aggregate volume expansion above twenty percent through late 2027 confirms successful patent-cliff absorption.

Key insights

MARITIME Phase 3 patient discontinuation rates exceeding fifteen percent during 2027 readouts signals severe tolerability failure.
Trailing free cash flow falling below nine billion dollars over the next four quarters demands structural reassessment.

Company Financial Analysis

Amgen Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Amgen's recent earnings tell a story of commercial resilience overcoming regulatory and generic headwinds. Total revenue reached $38.1 billion over the trailing twelve months, powered by nearly ten percent growth in the second quarter of 2026. Rapid double-digit volume expansion in newer treatments like Repatha and rare-disease therapies from the Horizon acquisition successfully offset a thirty-three percent drop in older bone-health drugs facing biosimilar competition. Reported GAAP net income surged to $12.65 billion on an operating basis, though headline growth was magnified by declining acquisition-related accounting amortization rather than pure operational improvement. More importantly, underlying free cash flow remained exceptionally sturdy at $10.18 billion, proving that Amgen generates dependable cash to manage patent expirations.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 36.7B	USD 7.7B	USD 8.1B
2024	USD 33.4B	USD 4.1B	USD 10.4B
2023	USD 28.2B	USD 6.7B	USD 7.4B
2022	USD 26.3B	USD 6.6B	USD 8.8B
2021	USD 26B	USD 5.9B	USD 8.4B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	23.0x	TTM	Native	USD / USD
2024	34.5x	TTM	Native	USD / USD
2023	23.2x	TTM	Native	USD / USD
2022	21.6x	Annual	Native	USD / USD
2021	21.6x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Profitability margins staged a strong recovery following the initial digestion of the Horizon merger. Gross margins rebounded to 70.8% in 2025 as inventory write-ups rolled off, while GAAP operating margins climbed to 36.8% in the second quarter of 2026. Synergies from specialized sales forces and strict administrative overhead control drove this operational rebound. Beneath the surface, non-GAAP operating margins held steady near 48.4%. While biosimilar competition against Prolia and mandatory Medicare discounts on Enbrel exert downward pressure on legacy lines, shifting product mix toward high-margin rare-disease treatments and manufacturing efficiencies should keep consolidated margins structurally healthy over the medium term.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 10.7B	29.1%	21.0%
2024	USD 7.3B	21.7%	12.2%
2023	USD 7.9B	28.0%	23.8%
2022	USD 9.6B	36.3%	24.9%
2021	USD 7.6B	29.4%	22.7%

Balance sheet and leverage

AI Review

Amgen's balance sheet continues to digest the $27.8 billion acquisition of Horizon Therapeutics, carrying approximately $51.9 billion to $57.3 billion in gross debt against $14.0 billion in liquid cash reserves. While debt-to-equity remains elevated at 6.31, strong operating earnings support an interest coverage ratio above 4.2 times, ensuring solid debt-service capacity. Management has demonstrated commendable capital discipline by halting share repurchases to focus excess cash on retiring senior notes. In an elevated interest rate environment where refinancing carries higher coupons, paying down debt protects credit ratings and steadily transfers enterprise value into equity value for shareholders.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 54.6B	USD 9.1B	USD 45.5B net debt	1.14x
2024	USD 60.1B	USD 12B	USD 48.1B net debt	1.26x
2023	USD 64.6B	USD 10.9B	USD 53.7B net debt	1.65x
2022	USD 38.9B	USD 9.3B	USD 31.3B net debt	1.41x
2021	USD 33.3B	USD 8B	USD 25.3B net debt	1.59x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Amgen operates a capital-efficient business model, keeping physical capital expenditures around five percent of revenue, or roughly $1.86 billion to $2.6 billion annually. These funds support advanced, continuous biomanufacturing facilities in Ohio and North Carolina, securing low unit costs and preventing supply bottlenecks for upcoming biologics. In contrast, research and development spending rose aggressively to nearly $7.0 billion, absorbing almost nineteen percent of revenue. This capital intensity reflects the extensive Phase 3 clinical trial program for MariTide across obesity, diabetes, and cardiovascular indications. Management is intentionally directing resources toward proprietary clinical assets to build high-margin replacement revenue for expiring blockbusters.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 1.9B	USD 7B
2024	USD 1.1B	USD 6B
2023	USD 1.1B	USD 4.8B
2022	USD 936M	USD 4.4B
2021	USD 880M	USD 6.3B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	NEUTRAL	21	+5.6%	Not available	ORIGINAL
5Y	NEUTRAL	100	+49.2%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	374.08	386.48	393.36	14
+6M	March 18, 2027	355.38	385.78	416.96	14
+9M	June 18, 2027	334.05	392.18	429.47	14
+1Y	September 18, 2027	324.03	398.53	446.65	14
+15M	December 18, 2027	327.27	407.95	455.71	14
+18M	March 18, 2028	321.17	413.71	473.94	14
+21M	June 18, 2028	317.96	423.8	488.16	14
+2Y	September 18, 2028	327.49	430.19	507.4	14
+27M	December 18, 2028	320.94	439.79	517.55	14
+30M	March 18, 2029	320.94	446.67	533.08	14
+33M	June 18, 2029	324.15	454.16	554.4	14
+3Y	September 18, 2029	330.64	461.86	571.03	14
+39M	December 18, 2029	337.25	468.78	576.74	14
+42M	March 18, 2030	340.62	475.35	594.04	14
+45M	June 18, 2030	337.22	480.87	605.92	14
+4Y	September 18, 2030	343.96	487.46	624.1	14
+51M	December 18, 2030	347.4	495.84	630.34	14
+54M	March 18, 2031	350.87	500.01	642.95	14
+57M	June 18, 2031	357.89	507.87	655.81	14
+5Y	September 18, 2031	361.47	515.23	668.92	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The independently supported common pattern confirms that Amgen's underlying business is not stagnating, but undergoing an operational rotation. Six key growth drivers—spearheaded by Repatha, Evenity, Tezspire, and Horizon orphan assets—are expanding at twenty-six percent annually and represent nearly seventy percent of product sales, generating over ten billion dollars in annual free cash flow. This operational reality firmly refutes extreme collapse theses. Conversely, reports projecting rapid multiple expansion above twenty-five times forward earnings rely on correlated, overly optimistic assumptions regarding MariTide trial execution and frictionless obesity commercialization against entrenched giants. The strongest contrarian critique rightly emphasizes that imminent denosumab biosimilars and Inflation Reduction Act price caps strip high-margin legacy cash flows just as elevated benchmark interest rates elevate debt servicing on fifty-plus billion dollars of gross obligations. Relative weights prioritize evidence-grounded frameworks that balance core specialty volume resilience against legitimate patent-cliff headwinds and scheduled acquisition amortization runoff.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight8.3/100

Delivers rigorous primary-source accounting verification, distinguishing non-cash acquisition amortization runoff from operating cash flows, while tracking IMDELLTRA clinical milestones. The analysis maintains balanced skepticism regarding pipeline optionality and valuation sensitivity in a high-yield macroeconomic regime.

AI RESEARCHER

Universal Investor AI

The Polymath

The Visionary

Gemini 3.8 Flash

Weight5.6/100

Presents a rigorous contrarian case examining GIP-antagonism biological trade-offs, titration challenges, and steep loss-of-exclusivity arithmetic. However, its severe projected multi-year drawdown understates the structural earnings floor provided by durable rare-disease and cardiovascular cash flows.

Skip to references

Research Provenance

References & Context

This Amgen consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 75 deduplicated sources retained for this batch.

01Fact Sheet: Medicare Drug Price Negotiation Program June 2023cms.gov
02Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026cms.gov
03AMGEN INC - Form 10-Q - FY2026sec.gov
04AMGEN INC - Form 10-Q - FY2026sec.gov
05amgen reports first quarter 2026 financial resultssec.gov
06amgn-20260630sec.gov
07Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White Housewhitehouse.gov
08Amgen Inc Earnings - Analysis & Highlights for Q2 2026alpha-sense.com
09AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS| Amgenamgen.com
10IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER| Amgenamgen.com
11RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS| Amgenamgen.com
12AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR | Amgen Inc.amgen.gcs-web.com
13MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes | Applied Clinical Trials Onlineappliedclinicaltrialsonline.com
14Amgen (AMGN) Stock Analysis — Quality Score & Fair Valuebeanvest.com
15Amgen SWOT Analysis – businessmodelcanvastemplate.combusinessmodelcanvastemplate.com

And 60 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.